Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Blue Jet Healthcare Limited

BLUEJET · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹504.55

+₹1.00 (+0.20%)(1D)

₹325.0052 Week Range₹688.50

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

59/100

Valuation

8/100

Quality

86/100

Growth

51/100

Health

99/100

Momentum

54/100

Valuation
8
Quality
86
Growth
51
Health
99
Momentum
54

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Blue Jet Healthcare Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹504.55

Market cap

₹8,753 Cr

P/E ratio

37.26

P/B ratio

6.44

Dividend yield

Not available

ROE

Not available

RSI 14

42.26

1Y return

Not available

Blue Jet Healthcare Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Blue Jet Healthcare Limited (BLUEJET) stock page cover?

Blue Jet Healthcare Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for BLUEJET?

Blue Jet Healthcare Limited is currently shown with a delayed price near ₹504.55, P/E 37.26.

Does the BLUEJET page provide investment advice?

No. The BLUEJET page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

SUPRIYA

Supriya Lifescience Limited · Healthcare

CONCORDBIO

Concord Biotech Limited · Healthcare

ONESOURCE

Onesource Specialty Pharma Limited · Healthcare

Monte Carlo Simulation & Walk-Forward Optimization for Indian Stock Strategies

Stress-test equity strategies using Monte Carlo permutation and walk-forward optimization across Indian crises (2008 GFC, 2020 COVID, rate hikes) on Anvest.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Blue Jet Healthcare is an Indian pharmaceutical ingredient and intermediate company specializing in contrast media products and high-intensity sweeteners. It operates globally, serving pharmaceutical, nutraceutical, and food industries, holding a significant position in its niche segments.

BiotechnologyFounded:1968CEO/MD:Akshay BansalHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Revenue growth: -8.0%FY26 growth
EPS growth: -18.8%FY26 growth
CFO / PAT: 1.35×FY26

What Looks Strong

QualityQuality score is supported by healthy return on equity (ROE 18.2%).
Cash FlowOperating cash flow was 1.35× total net profit in FY26.

What to Watch

RevenueRevenue declined about 8% in FY26 (standalone: ₹1,030 cr → ₹947 cr). Watch whether the next results confirm a trend or a one-off.
EarningsNet profit fell about 19% in FY26 (standalone: ₹305 cr → ₹248 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~34.9% to ~28.5% in FY26 (standalone). Watch input costs and pricing in the next two results.

Reports a single operating segment in its results filings.
The company generates revenue by manufacturing and selling pharmaceutical products.
Key product categories contributing to turnover include Contrast Media (53%), High Intensity Sweeteners (14%), and pharmaceutical intermediaries and Active Pharmaceutical Ingredients (33%).

FY26 (standalone): revenue ₹947 cr, down 8% from ₹1,030 cr in FY25; net profit ₹248 cr, down 19% from ₹305 cr in FY25.
FY26 (standalone): operating cash flow ₹334 cr (1.3× net profit); debt/equity 0.03×.
Latest quarter to Jun 2026 (standalone): revenue ₹293 cr (down 17% year on year); net profit ₹78.3 cr.

Revenue is concentrated in three main product categories, with Contrast Media accounting for over half of the total turnover